By Fineline Cube 
German pharmaceutical leader Boehringer Ingelheim (BI) announced that its Shanghai-based subsidiary, Boehringer Ingelheim Biopharmaceuticals (China) Ltd., has successfully completed a Good Manufacturing Practice (GMP) inspection by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). This approval authorizes the Pudong production site to supply innovative biologic therapies to the Japanese market.
Significance of the Approval
The successful PMDA inspection marks a significant milestone for Boehringer Ingelheim’s global commercial strategy. With this approval, the company can now expand its existing commercial distribution network, which previously covered China, the U.S., and Europe, to include Japan. This expansion underscores the company’s commitment to providing high-quality biologics to patients worldwide.-Fineline Info & Tech